Hoon Eng Khoo
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Hoon Eng Khoo has a total of 19 co-authors. Here are the top co-authors by number of shared publications:
Chang-Li Wei
Department of Biochemistry, Faculty of Medicine, National University of Singapore, 119260, Singapore
2 shared publicationsKang-Hoe Lee
2 shared publicationsWei-Min Hon
2 shared publicationsBeatrice J Goh
Department of Biochemistry, Faculty of Medicine, National University of Singapore, Block MD4A, #01-03 5 Science Drive 2, 117597, Singapore
1 shared publicationBee Tee Tan
1 shared publicationChang‐Li Wei
Department of Paediatrics, Faculty of Medicine, National University of Singapore, 10 Kent Ridge Crescent, Singapore 119260, Singapore
1 shared publication
Latest Publications
- Open Access
- 1 January 2006
- Published by Baishideng Publishing Group Inc. in World Journal of Gastroenterology
- Vol. 12 (4) , 588-594
Nitric oxide synthase and heme oxygenase expressions in human liver cirrhosis
AIM: Portal hypertension is a common complication of liver cirrhosis. Intrahepatic pressure can be elevated in several ways. Abnormal architecture affecting the vasculature, an increase in vasoconstrictors and increased circulation from the splanchnic viscera into the portal system may all contribute. It follows that endogenous vasodilators may be able to alleviate the hypertension. We therefore aimed to investigate the levels of endogenous vasodilators, nitric oxide (NO) and carbon monoxide (CO) through the expression of nitric oxide synthase (NOS) and heme oxygenase (HO). METHOD: Cirrhotic (n
- 1 January 2006
- Published by Baishideng Publishing Group Inc. in World Journal of Gastroenterology
- Vol. 12 (4) , 588-594
Open AccessNitric oxide synthase and heme oxygenase expressions in human liver cirrhosis
AIM: Portal hypertension is a common complication of liver cirrhosis. Intrahepatic pressure can be elevated in several ways. Abnormal architecture affecting the vasculature, an increase in vasoconstrictors and increased circulation from the splanchnic viscera into the portal system may all contribute. It follows that endogenous vasodilators may be able to alleviate the hypertension. We therefore aimed to investigate the levels of endogenous vasodilators, nitric oxide (NO) and carbon monoxide (CO) through the expression of nitric oxide synthase (NOS) and heme oxygenase (HO). METHOD: Cirrhotic (n
- 20 May 2005
- Published by Wiley in Liver International
- Vol. 25 (3) , 647-656
Chronic administration of aminoguanidine reduces vascular nitric oxide production and attenuates liver damage in bile duct‐ligated rats
Background: Nitric oxide (NO) has been implicated in the pathogenesis of liver cirrhosis. This study investigated the activity of nitric oxide synthase (NOS) in cirrhosis induced by bile duct‐ligation (BDL) with NOS inhibitors.Method: Three days after operation, rats were randomized to receive aminoguanidine (AG, 25 mg/kg/day) or l‐nG‐nitro‐l‐arginine methyl ester (l‐NAME, 10 mg/kg/day) for 21 days.Results: Vascular NO production, which was increased in BDL cirrhotic rats, was reduced by 75% with AG but not l‐NAME chronic administration. AG treatment attenuated liver damage, while l‐NAME aggravated it. AG significantly suppressed inducible NOS (iNOS) expression in aorta of BDL rats at both mRNA and protein level, but much less efficient in reducing it in liver. In contrast, endothelial NOS (eNOS) expression was not markedly affected. Calcium‐independent NOS activity, which was dramatically increased in aorta of BDL rats, was abolished by AG treatment. In liver, however, both calcium‐dependent and ‐independent NOS activity were increased by AG treatment.Conclusion: Chronic administration of AG could reduce systemic NO levels as well as suppress iNOS expression and activity in aorta of BDL rats. It also improved liver function, possibly because of its ability to increase hepatic NOS activity, and to correct the systemic hemodynamic disorders by decreasing vascular NO production.
- 20 May 2005
- Published by Wiley in Liver International
- Vol. 25 (3) , 647-656
Chronic administration of aminoguanidine reduces vascular nitric oxide production and attenuates liver damage in bile duct‐ligated rats
Background: Nitric oxide (NO) has been implicated in the pathogenesis of liver cirrhosis. This study investigated the activity of nitric oxide synthase (NOS) in cirrhosis induced by bile duct‐ligation (BDL) with NOS inhibitors.Method: Three days after operation, rats were randomized to receive aminoguanidine (AG, 25 mg/kg/day) or l‐nG‐nitro‐l‐arginine methyl ester (l‐NAME, 10 mg/kg/day) for 21 days.Results: Vascular NO production, which was increased in BDL cirrhotic rats, was reduced by 75% with AG but not l‐NAME chronic administration. AG treatment attenuated liver damage, while l‐NAME aggravated it. AG significantly suppressed inducible NOS (iNOS) expression in aorta of BDL rats at both mRNA and protein level, but much less efficient in reducing it in liver. In contrast, endothelial NOS (eNOS) expression was not markedly affected. Calcium‐independent NOS activity, which was dramatically increased in aorta of BDL rats, was abolished by AG treatment. In liver, however, both calcium‐dependent and ‐independent NOS activity were increased by AG treatment.Conclusion: Chronic administration of AG could reduce systemic NO levels as well as suppress iNOS expression and activity in aorta of BDL rats. It also improved liver function, possibly because of its ability to increase hepatic NOS activity, and to correct the systemic hemodynamic disorders by decreasing vascular NO production.
- Open Access
- 1 January 2004
- Published by Baishideng Publishing Group Inc. in World Journal of Gastroenterology
- Vol. 11 (3) , 362-367
Temporal expression of hepatic inducible nitric oxide synthase in liver cirrhosis
Temporal expression of hepatic inducible nitric oxide synthase in liver cirrhosis
- 1 January 2004
- Published by Baishideng Publishing Group Inc. in World Journal of Gastroenterology
- Vol. 11 (3) , 362-367
Open AccessTemporal expression of hepatic inducible nitric oxide synthase in liver cirrhosis
Temporal expression of hepatic inducible nitric oxide synthase in liver cirrhosis
- 22 April 2003
- Published by Wiley in Medical Education
- Vol. 37 (5) , 401-409
Implementation of problem‐based learning in Asian medical schools and students' perceptions of their experience
Background Since the introduction of problem‐based learning (PBL) at McMaster University in 1969, many medical schools in the USA, Canada and Europe have included PBL in their curricula. In the past decade, many medical schools in Asia have also done so. However, so far no one has questioned whether the outcomes expected of the learner in a PBL setting are applicable to students from different cultural upbringings. Aim The aim of this study was to investigate the implementation of PBL in Asian medical schools, their students' perceptions of this new mode of teaching/learning and how the problems that have arisen may be overcome. Method Published reports and conference presentations were gathered on the implementation of PBL in some Asian medical schools and comparisons of the experiences in PBL of Asian and students of other ethnic backgrounds. Results Most Asian medical schools and their students appear to be positive about adapting to PBL in their curriculum. The positive and negative observations appear to be similar to those experienced in non‐Asian medical schools. The problems that arose for students in Asian medical schools in the early stages of implementing PBL appear to have been overcome after a period of adjustment with the help of supportive and open‐minded tutors. The reports also suggested that trigger problems should be carefully designed to make them relevant and interesting for the students. Conclusion Strong support from the academic administrators (dean and other staff responsible for implementation of the curriculum) in the introduction of PBL into the curriculum and careful training of both faculty and students appear to be key factors to ensure the successful implementation of PBL in Asian medical schools.
- 22 April 2003
- Published by Wiley in Medical Education
- Vol. 37 (5) , 401-409
Implementation of problem‐based learning in Asian medical schools and students' perceptions of their experience
Background Since the introduction of problem‐based learning (PBL) at McMaster University in 1969, many medical schools in the USA, Canada and Europe have included PBL in their curricula. In the past decade, many medical schools in Asia have also done so. However, so far no one has questioned whether the outcomes expected of the learner in a PBL setting are applicable to students from different cultural upbringings. Aim The aim of this study was to investigate the implementation of PBL in Asian medical schools, their students' perceptions of this new mode of teaching/learning and how the problems that have arisen may be overcome. Method Published reports and conference presentations were gathered on the implementation of PBL in some Asian medical schools and comparisons of the experiences in PBL of Asian and students of other ethnic backgrounds. Results Most Asian medical schools and their students appear to be positive about adapting to PBL in their curriculum. The positive and negative observations appear to be similar to those experienced in non‐Asian medical schools. The problems that arose for students in Asian medical schools in the early stages of implementing PBL appear to have been overcome after a period of adjustment with the help of supportive and open‐minded tutors. The reports also suggested that trigger problems should be carefully designed to make them relevant and interesting for the students. Conclusion Strong support from the academic administrators (dean and other staff responsible for implementation of the curriculum) in the introduction of PBL into the curriculum and careful training of both faculty and students appear to be key factors to ensure the successful implementation of PBL in Asian medical schools.
- 1 October 2002
- Published by Bentham Science Publishers Ltd. in Current Pharmaceutical Design
- Vol. 8 (22) , 1973-1985
Cancer-Homing Toxins
Cancer-homing toxins are a group of man-made cytotoxic molecules targeting cancer cells. In the past decade they have demonstrated potential as cancer therapeutics. These molecules contain a toxin, natural or usually derivatized, connected to a cancerhoming module, such as a monoclonal antibody or growth factor or their derivatives. Various cancer-homing toxins have been designed and tested in cell-lines, animalmodels and clinical trials. We review some of these data and discuss ways to better design cancer-homing toxins in the light of advances in cancer genomics, antibodyengineering techniques and computational algorithms.
- 1 October 2002
- Published by Bentham Science Publishers Ltd. in Current Pharmaceutical Design
- Vol. 8 (22) , 1973-1985
Cancer-Homing Toxins
Cancer-homing toxins are a group of man-made cytotoxic molecules targeting cancer cells. In the past decade they have demonstrated potential as cancer therapeutics. These molecules contain a toxin, natural or usually derivatized, connected to a cancerhoming module, such as a monoclonal antibody or growth factor or their derivatives. Various cancer-homing toxins have been designed and tested in cell-lines, animalmodels and clinical trials. We review some of these data and discuss ways to better design cancer-homing toxins in the light of advances in cancer genomics, antibodyengineering techniques and computational algorithms.
- 2 August 2002
- Published by Wiley in Clinical and Experimental Pharmacology and Physiology
- Vol. 29 (9) , 802-806
Bioactive proteins from stonefish venom
Summary: 1. Of all the venomous fish known, the stonefish is one of the most commonly encountered by man. Studies on its venom started in the 1950s, but little work was performed after that until several groups revived interest in the venom in the 1980s after easier accessibility to the fish.2. Stonefish venom is a mixture of proteins, containing several enzymes, including hyaluronidase of high specific activity. A purified stonefish hyaluronidase has been characterized.3. Several of the effects of the crude venom have been isolated to a protein lethal factor that has cytolytic, neurotoxic and hypotensive activity. This protein is stonustoxin from Synanceja horrida, trachynilysin from Synanceja trachynis and verrucotoxin from Synanceja verrucosa.4. The biochemical properties and activities of these protein lethal factors are reviewed.
- 2 August 2002
- Published by Wiley in Clinical and Experimental Pharmacology and Physiology
- Vol. 29 (9) , 802-806
Bioactive proteins from stonefish venom
Summary: 1. Of all the venomous fish known, the stonefish is one of the most commonly encountered by man. Studies on its venom started in the 1950s, but little work was performed after that until several groups revived interest in the venom in the 1980s after easier accessibility to the fish.2. Stonefish venom is a mixture of proteins, containing several enzymes, including hyaluronidase of high specific activity. A purified stonefish hyaluronidase has been characterized.3. Several of the effects of the crude venom have been isolated to a protein lethal factor that has cytolytic, neurotoxic and hypotensive activity. This protein is stonustoxin from Synanceja horrida, trachynilysin from Synanceja trachynis and verrucotoxin from Synanceja verrucosa.4. The biochemical properties and activities of these protein lethal factors are reviewed.
- 4 March 2002
- Published by Elsevier in Biochemical Pharmacology
- Vol. 63 (6) , 1113-1118
Characterization of the mechanism underlying stonustoxin-mediated relaxant response in the rat aorta in vitro
- 4 March 2002
- Published by Elsevier in Biochemical Pharmacology
- Vol. 63 (6) , 1113-1118
Characterization of the mechanism underlying stonustoxin-mediated relaxant response in the rat aorta in vitro
- 30 January 2002
- Published by Elsevier in Biochemical Pharmacology
- Vol. 63 (6) , 1043-1050
Induction of arginase II in livers of bile duct-ligated rats
- 30 January 2002
- Published by Elsevier in Biochemical Pharmacology
- Vol. 63 (6) , 1043-1050
Induction of arginase II in livers of bile duct-ligated rats
- 18 December 2001
- Published by Elsevier in Biochemical Pharmacology
- Vol. 63 (2) , 273-282
The signalling pathway for BCG-induced interleukin-6 production in human bladder cancer cells
- 18 December 2001
- Published by Elsevier in Biochemical Pharmacology
- Vol. 63 (2) , 273-282
The signalling pathway for BCG-induced interleukin-6 production in human bladder cancer cells